Literature DB >> 16121363

A serological survey on neutralizing antibody titer of SARS convalescent sera.

Jian-San Zhang1, Jiang-Ting Chen, Yu-Xuan Liu, Zhen-Shan Zhang, Hong Gao, Yan Liu, Xu Wang, Ye Ning, Yu-Fen Liu, Qiang Gao, Jian-Guo Xu, Chuan Qin, Xiao-Ping Dong, Wei-Dong Yin.   

Abstract

A seroepidemiologic study was conducted in North China in 2003 to determine the neutralizing antibody titer of severe acute respiratory syndrome (SARS) convalescent sera. A total of 99 SARS convalescent serum samples were collected from patients from the Inner Mongolia Autonomous Region, Hebei Province, and Beijing 35-180 days after the onset of symptoms. The anti-SARS antibodies were detected by enzyme-linked immunosorbent assay (ELISA), neutralization assay, and Western blot. Eighty-seven serum samples were confirmed to be positive for SARS antibodies. The neutralizing antibody titer of the 87 positive sera was analyzed quantitatively by neutralization assay. The geometric mean titer (GMT) of the 87 convalescent sera was 1:61. The Kolmogorov-Smirnov test showed that the neutralizing antibody titers conform to normal distribution, which suggests that the average anti-SARS antibody level in this study was representative of the convalescent antibody level of the SARS population. This result could be useful for the development and quality control of SARS vaccines. (c) 2005 Wiley-Liss, Inc

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16121363      PMCID: PMC7167078          DOI: 10.1002/jmv.20431

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  14 in total

1.  [Detection of the anti-SARS-coronavirus specific antibody levels in 156 SARS patients].

Authors:  Hai-Bao Wang; Jing-Han Liu; Xi-Lin Ouyang; Yang Yu; Shu-Xuan Ma; Xi-Jin Li; Liu-Cai Lu; Ya-Ping Tian; Hong-Ying Liu; Hong-Min Xu; Wei Yao
Journal:  Zhongguo Shi Yan Xue Ye Xue Za Zhi       Date:  2003-10

2.  Identification of a novel coronavirus in patients with severe acute respiratory syndrome.

Authors:  Christian Drosten; Stephan Günther; Wolfgang Preiser; Sylvie van der Werf; Hans-Reinhard Brodt; Stephan Becker; Holger Rabenau; Marcus Panning; Larissa Kolesnikova; Ron A M Fouchier; Annemarie Berger; Ana-Maria Burguière; Jindrich Cinatl; Markus Eickmann; Nicolas Escriou; Klaus Grywna; Stefanie Kramme; Jean-Claude Manuguerra; Stefanie Müller; Volker Rickerts; Martin Stürmer; Simon Vieth; Hans-Dieter Klenk; Albert D M E Osterhaus; Herbert Schmitz; Hans Wilhelm Doerr
Journal:  N Engl J Med       Date:  2003-04-10       Impact factor: 91.245

3.  Medicine. Caution urged on SARS vaccines.

Authors:  Eliot Marshall; Martin Enserink
Journal:  Science       Date:  2004-02-13       Impact factor: 47.728

4.  Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice.

Authors:  Himani Bisht; Anjeanette Roberts; Leatrice Vogel; Alexander Bukreyev; Peter L Collins; Brian R Murphy; Kanta Subbarao; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-19       Impact factor: 11.205

5.  Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice.

Authors:  Kanta Subbarao; Josephine McAuliffe; Leatrice Vogel; Gary Fahle; Steven Fischer; Kathleen Tatti; Michelle Packard; Wun-Ju Shieh; Sherif Zaki; Brian Murphy
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

6.  Profile of antibodies to the nucleocapsid protein of the severe acute respiratory syndrome (SARS)-associated coronavirus in probable SARS patients.

Authors:  Xuan Liu; Yulin Shi; Ping Li; Linhai Li; Yanping Yi; Qingjun Ma; Cheng Cao
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

7.  Serologic and molecular biologic methods for SARS-associated coronavirus infection, Taiwan.

Authors:  Ho-Sheng Wu; Shu-Chun Chiu; Tsan-Chang Tseng; Szu-Fong Lin; Jih-Hui Lin; Yu-Hen Hsu; Mei-Ching Wang; Tsuey-Li Lin; Wen-Zieh Yang; Tian-Lin Ferng; Kai-Hung Huang; Li-Ching Hsu; Li-Li Lee; Jyh-Yuan Yang; Hour-Young Chen; Shun-Pi Su; Shih-Yan Yang; Shih-Yan Lin; Ting-Hsiang Lin; Ih-Sen Su
Journal:  Emerg Infect Dis       Date:  2004-02       Impact factor: 6.883

8.  Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome.

Authors:  Thijs Kuiken; Ron A M Fouchier; Martin Schutten; Guus F Rimmelzwaan; Geert van Amerongen; Debby van Riel; Jon D Laman; Ton de Jong; Gerard van Doornum; Wilina Lim; Ai Ee Ling; Paul K S Chan; John S Tam; Maria C Zambon; Robin Gopal; Christian Drosten; Sylvie van der Werf; Nicolas Escriou; Jean-Claude Manuguerra; Klaus Stöhr; J S Malik Peiris; Albert D M E Osterhaus
Journal:  Lancet       Date:  2003-07-26       Impact factor: 79.321

9.  SARS under control, but lab-safety questions remain.

Authors:  Jonathan Watts
Journal:  Lancet       Date:  2004-05-29       Impact factor: 79.321

10.  Evaluation of antibody responses against SARS coronaviral nucleocapsid or spike proteins by immunoblotting or ELISA.

Authors:  Li-Rung Huang; Chi-Ming Chiu; Shiou-Hwei Yeh; Wen-Hung Huang; Po-Ren Hsueh; Wen-Zieh Yang; Jyh-Yuan Yang; Ih-Jen Su; Shan-Chwen Chang; Pei-Jer Chen
Journal:  J Med Virol       Date:  2004-07       Impact factor: 2.327

View more
  39 in total

1.  A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.

Authors:  Meagan Bolles; Damon Deming; Kristin Long; Sudhakar Agnihothram; Alan Whitmore; Martin Ferris; William Funkhouser; Lisa Gralinski; Allison Totura; Mark Heise; Ralph S Baric
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

2.  The convalescent sera option for containing COVID-19.

Authors:  Arturo Casadevall; Liise-Anne Pirofski
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 3.  An overview of key potential therapeutic strategies for combat in the COVID-19 battle.

Authors:  Gaurav Das; Surojit Ghosh; Shubham Garg; Satyajit Ghosh; Aniket Jana; Ramkamal Samat; Nabanita Mukherjee; Rajsekhar Roy; Surajit Ghosh
Journal:  RSC Adv       Date:  2020-07-28       Impact factor: 4.036

Review 4.  Deployment of convalescent plasma for the prevention and treatment of COVID-19.

Authors:  Evan M Bloch; Shmuel Shoham; Arturo Casadevall; Bruce S Sachais; Beth Shaz; Jeffrey L Winters; Camille van Buskirk; Brenda J Grossman; Michael Joyner; Jeffrey P Henderson; Andrew Pekosz; Bryan Lau; Amy Wesolowski; Louis Katz; Hua Shan; Paul G Auwaerter; David Thomas; David J Sullivan; Nigel Paneth; Eric Gehrie; Steven Spitalnik; Eldad A Hod; Lewis Pollack; Wayne T Nicholson; Liise-Anne Pirofski; Jeffrey A Bailey; Aaron Ar Tobian
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

5.  Autoimmune Processes Involved in Organ System Failure Following Infection with SARS-CoV-2.

Authors:  Steven E Kornguth; Robert J Hawley
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Convalescent plasma therapy in patients with moderate-to-severe COVID-19: A study from Indonesia for clinical research in low- and middle-income countries.

Authors:  Marliana S Rejeki; Nana Sarnadi; Retno Wihastuti; Vininta Fazharyasti; Wisvici Y Samin; Frilasita A Yudhaputri; Edison Johar; Neni Nurainy; Novilia S Bachtiar; David H Muljono
Journal:  EClinicalMedicine       Date:  2021-06-04

7.  Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants.

Authors:  Damon Deming; Timothy Sheahan; Mark Heise; Boyd Yount; Nancy Davis; Amy Sims; Mehul Suthar; Jack Harkema; Alan Whitmore; Raymond Pickles; Ande West; Eric Donaldson; Kristopher Curtis; Robert Johnston; Ralph Baric
Journal:  PLoS Med       Date:  2006-12       Impact factor: 11.069

Review 8.  COVID-19 Pandemic and the Convalescent Plasma Therapy: Possible Benefits and Risks.

Authors:  Rashed Noor; Nishat Tasnim; Chandrika Saha
Journal:  Curr Clin Microbiol Rep       Date:  2021-07-03

9.  Animal models and vaccines for SARS-CoV infection.

Authors:  Anjeanette Roberts; Elaine W Lamirande; Leatrice Vogel; Jadon P Jackson; Christopher D Paddock; Jeannette Guarner; Sherif R Zaki; Timothy Sheahan; Ralph Baric; Kanta Subbarao
Journal:  Virus Res       Date:  2007-05-11       Impact factor: 3.303

10.  Pandemic COVID-19: Current status and challenges of antiviral therapies.

Authors:  Winglam Chan; Betsy He; Xiong Wang; Ming-Liang He
Journal:  Genes Dis       Date:  2020-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.